SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-23-044579
Filing Date
2023-08-25
Accepted
2023-08-25 16:15:55
Documents
18
Period of Report
2023-10-10

Document Format Files

Seq Description Document Type Size
1 DEF 14A acst-20230825.htm   iXBRL DEF 14A 1378515
2 GRAPHIC img180421716_0.jpg GRAPHIC 9944
3 GRAPHIC img180421716_1.jpg GRAPHIC 45650
4 GRAPHIC img180421716_2.jpg GRAPHIC 44140
5 GRAPHIC img180421716_3.jpg GRAPHIC 784624
6 GRAPHIC img180421716_4.jpg GRAPHIC 586865
  Complete submission text file 0000950170-23-044579.txt   6019869

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT acst-20230825_def.xml EX-101.DEF 4901
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT acst-20230825_lab.xml EX-101.LAB 11614
9 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT acst-20230825.xsd EX-101.SCH 4836
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT acst-20230825_pre.xml EX-101.PRE 6434
13 EXTRACTED XBRL INSTANCE DOCUMENT acst-20230825_htm.xml XML 322282
Mailing Address 3009, BOUL. DE LA CONCORDE EAST SUITE 102 LAVAL A8 H7E 2B5
Business Address 3009, BOUL. DE LA CONCORDE EAST SUITE 102 LAVAL A8 H7E 2B5 450-686-4555
Acasti Pharma Inc. (Filer) CIK: 0001444192 (see all company filings)

IRS No.: 000000000 | State of Incorp.: A8 | Fiscal Year End: 0331
Type: DEF 14A | Act: 34 | File No.: 001-35776 | Film No.: 231208473
SIC: 2834 Pharmaceutical Preparations